Clinical Trials Arena June 16, 2025
At OCT UK & Ireland, Aditya Kotta, Head of Business Development at Novotech, discussed the emerging biotech funding environment and market trends.
An analysis of clinical trial registries, including ClinicalTrials.gov and Australian and New Zealand registries, has shown a 20% reduction in overall trial activity compared to this time last year, with oncology trials being hit hardest, said Aditya Kotta, Head of Business Development of US and EU at global contract research organisation (CRO) Novotech.
In a presentation at the 12th annual Outsourcing in Clinical Trials (OCT) UK and Ireland, Kotta discussed the emerging biotech landscape and how the market and funding conditions are driving decision-making when it comes to planning early phase programmes. The meeting took place on 10–11...
Today's Sponsors
Today's Sponsor